

Substitute for Form 1449/A/PTO

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|


| | |
|-------------------------------|----------------------------------|
| Application Number | 09/735,363 |
| Filing Date | December 12, 2000 |
| First Named Inventor | Phillips <i>et al.</i> |
| Group Art Unit | 1635 |
| Examiner Name | Mary Schmidt |
| Attorney Docket Number | 02811-0181 (42368-250224) |

[illegible][illegible]

Examiner
Signature

Date
Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.




Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|---|--------------------------|---------------------------|
| Substitute for Form 1449/A/PTO | | Complete if Known | |
| | | Application Number | 09/735,363 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Filing Date | December 12, 2000 |
| | | First Named Inventor | Phillips <i>et al.</i> |
| | | Group Art Unit | 1635 |
| | | Examiner Name | Mary Schmidt |
| | | Attorney Docket Number | 02811-0181 (42368-250224) |
| Sheet | 2 | of | 4 |

| OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| J3 | BA | BALLAS <i>et al.</i> , "Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA," J. Immunol., September 1, 1996, p. 1840-1845, Vol. 157. | |
| | BB | BATES <i>et al.</i> , "Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding," J. Biol. Chem., September 10, 1999, Vol. 274, pp. 26369-26377. | |
| | BC | BRAUN <i>et al.</i> , "Cytotoxic T Cells Deficient in Both Functional Fas Ligand and Perforin Show Residual Cytolytic Activity yet Lose Their Capacity to Induce Lethal Acute Graft-Versus-Host Disease," J. Exp. Med., 1996, p. 657-661, Vol. 183. | |
| | BD | FAMULARO <i>et al.</i> , "Fas/Fas Ligand on the Road; An Apoptotic Pathway Common to AIDS, Autoimmunity, Lymphoproliferation and Transplantation," Med. Hypoth., 1999, p. 50-62, Vol. 53. | |
| | BE | FILION, M.C. <i>et al.</i> , "Inhibition of cell cycle progression and induction of apoptosis in leukemia cells by <i>Mycobacterium phlei</i> DNA and derived synthetic oligonucleotides." Clinical Cancer Research (November 7-10, 2000), Vol. 6, Supp.; Page 4571S. | |
| | BF | FILION, M.C. <i>et al.</i> , "Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells." British Journal of Cancer (January, 1999) 79(2) 229-35. | |
| | BG | FILION, M.C., <i>et al.</i> , "Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex." Cancer Immunology Immunotherapy (August, 2000), 49(6), pgs. 325-34. | |
| | BH | GRIFFITH, <i>et al.</i> , "Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege," Science, November 17, 1995, Vol. 270, pp. 1189-1192. | |
| | BI | HOCHHAUSER, D., "Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer," Anti-Cancer Drugs, 1997, Vol. 8, pp. 903-910. | |
| | BJ | KLINMAN <i>et al.</i> , "CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ ," Proc. Natl. Acad. Sci. USA, April, 1996, pp. 2879-2883, Vol. 93. | |
| | BK | KONDO <i>et al.</i> , "Essential Roles of the Fas Ligand in the Development of Hepatitis," Nature Med., April, 1997, pp. 409-413, Vol. 3, No. 4. | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 5/28/03 |
|--------------------|--|-----------------|---------|

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.



Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------------|
| Application Number | 09/735,363 |
| Filing Date | December 12, 2000 |
| First Named Inventor | Phillips <i>et al.</i> |
| Group Art Unit | 1635 |
| Examiner Name | Mary Schmidt |
| Attorney Docket Number | 02811-0181 (42368-250224) |


Sheet **3** of **4****OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|----------------------|--------------------------|---|----------------|
| J3 | CA | LIPFORD <i>et al.</i> , "CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants," Eur. J. Immunol., 1997, pp. 2340-2344, Vol.27. | |
| | CB | MORASSUTTI, <i>et al.</i> , "Correlation between cytotoxic effect and binding to nuclear proteins of oligomeric d(GT)n sequences in human cancer CCRF-CEM cell line," Minerva Biotech, June, 1995, pp. 176-181. | |
| | CC | MORASSUTTI, <i>et al.</i> , "Effect of Oligomer Length and Base Substitutions On The Cytotoxic Activity and Specific Nucelar Protein Recognition of GTn Oligonucleotides in the Human Leukemic CCRF-CEM Cell Line," Nucleosides and Nucleotides, 18(6&7), pp. 1711-1716 (1999). | |
| | CD | NAGATA, S., "Fas Ligand-Induced Apoptosis," Ann. Rev. Genet., 1999, pp. 29-55, Vol. 33. | |
| | CE | NISHIOKA <i>et al.</i> , "An Augmentation of Fas (CD95/APO-1) Antigen Induced by Radiation: Flow Cytometry Analysis of Lymphoma and Leukemia Cell Lines," Int. J. Mol. Med., 1999, pp. 275-278, Vol. 3. | |
| | CF | O'CONNELL, <i>et al.</i> , "The Fas Counterattack: Fas-Mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand," J. Exp. Med., September, 1996, pp. 1075-1082, Vol. 184. | |
| | CG | OWEN-SCHAUB <i>et al.</i> , "Fas and Fas Ligand Interactions in Malignant Disease (Review)," Int. J. Oncol., 2000, pp. 5-12, Vol. 17. | |
| | CH | Promega Catalog 1993/94, Revolutions in Science, cover and pp. 90-91. | |
| | CI | READER, S., <i>et al.</i> , "Identification of non-antisense phosphodiester oligonucleotides that induce cell cycle arrest and apoptosis in cancer cells." Clinical Cancer Research (November 7-10, 2000), Vol. 6, Supp.; Page 4571S. | |
| | CJ | SABELKO-DOWNES <i>et al.</i> , "The Role of Fas Ligand <i>in vivo</i> as a Cause and Regulator of Pathogenesis," Curr. Opin. Immunol., June, 2000, pp. 330-335, Vol. 12. | |
| | CK | SCAGGIANTE <i>et al.</i> , "Human Cancer Cell Lines Growth Inhibition by GT _n Oligodeoxyribonucleotides Recognizing Single-Stranded DNA-Binding Proteins," Eur. J. Biochem., March 1, 1998, pp. 207-215, Vol. 252. | |

Examiner
SignatureDate
Considered

5/28/03

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------------|
| Application Number | 09/879,668 |
| Filing Date | June 12, 2001 |
| First Named Inventor | Phillips <i>et al.</i> |
| Group Art Unit | 1632 |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 02811-0181 (42368-250224) |

Sheet 4 of 4

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|----------------------|--------------------------|--|----------------|
| J3 | DA | SHEARD <i>et al.</i> , "UP-Regulation of FAS (CD95) in Human p53 ^{wild-type} Cancer Cells Treated With Ionizing Radiation," Int. J. Cancer, 27 November, 1997, pp. 757-762, Vol. 73. | |
| | DB | VLASSOV <i>et al.</i> , "Transport of Oligonucleotides across Natural and Model Membranes," Biochem. Biophys. Acta., 1994, pp. 95-108, Vol. 1197. | |
| | DC | WAGNER, R., "Gene Inhibition Using Antisense Oligodeoxynucleotides," Nature, 1994, pp. 333-335, Vol. 372. | |
| | DD | WANG <i>et al.</i> , "Unmethylated CpG Motifs Protect Murine B Lymphocytes Against Fas-Mediated Apoptosis," Cellular Immunol., 1997, pp. 162-167, Vol. 180. | |
| | DE | WYLLIE <i>et al.</i> , "Cell Death: The Significance of Apoptosis," Int. Rev. Cytol., 1980, pp. 251-306, Vol. 68. | |
| | DF | WYLLIE A., "Glucocorticoid-Induced Thymocyte Apoptosis is Associated with Endogenous Endonuclease Activation," Nature, 1980, pp. 555-556, Vol. 284. | |
| | DG | YOONG <i>et al.</i> , "Fas/Fas Ligand Interaction in Human Colorectal Hepatic Metastases," Am. J. Pathol., March, 1999, pp. 693-703, Vol. 154. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 5/28/03 |
|-----------------------|--|--------------------|---------|

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.